Radiation plus two immunotherapy drugs shows promise in advanced cancers
NCT ID NCT02639026
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new way to treat advanced cancers that have spread. It combined a special type of radiation with two immunotherapy drugs (MEDI4736 and tremelimumab) to see if the combination is safe and tolerable. The study included 53 adults with advanced melanoma, lung, breast, or pancreatic cancer who had not responded to standard treatments. The main goal was to find the best dose and schedule while monitoring side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple